Prevalence of prurigo nodularis in the United States

Katherine A. Whang; Varun Mahadevan; Pegah R. Bakhshi; Kyle A. Williams; Sylvie Gabriel; Rajeev Chavda; Shawn G. Kwatra

doi:10.1016/j.jaip.2020.05.051

Prevalence of prurigo nodularis in the United States

Katherine A. Whang, Varun Mahadevan, Pegah R. Bakhshi, Kyle A. Williams, Sylvie Gabriel, Rajeev Chavda, Shawn G. Kwatra

School of Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	3240-3241
Number of pages	2
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	8
Issue number	9
DOIs	https://doi.org/10.1016/j.jaip.2020.05.051
State	Published - Oct 2020

ASJC Scopus subject areas

Immunology and Allergy

Access to Document

10.1016/j.jaip.2020.05.051

Cite this

@article{1b9f441689fe4e2f8cda3ef21884f6a0,

title = "Prevalence of prurigo nodularis in the United States",

author = "Whang, {Katherine A.} and Varun Mahadevan and Bakhshi, {Pegah R.} and Williams, {Kyle A.} and Sylvie Gabriel and Rajeev Chavda and Kwatra, {Shawn G.}",

note = "Funding Information: Conflicts of interest: S. G. Kwatra is a scientific advisory board member for Regeneron Pharmaceuticals, Pfizer Inc., Menlo Therapeutics, and Incyte Corporation. He is a consultant for Galderma S.A., Castle Biosciences, and Kinkisa Pharmaceuticals. He has received grant funding from Pfizer Inc. , Kiniksa Pharmaceuticals , and Galderma S.A. S. Gabriel and R. Chavda are employed by Galderma S.A. Galderma is conducting clinical trials of nemolizumab for the treatment of pruritus in prurigo nodularis. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: S.G.K. received a research grant from the Skin of Color Society and is a recipient of a Medical Dermatology Career Development Award from the Dermatology Foundation . Funding Information: S.G.K. received a research grant from the Skin of Color Society and is a recipient of a Medical Dermatology Career Development Award from the Dermatology Foundation.Conflicts of interest: S. G. Kwatra is a scientific advisory board member for Regeneron Pharmaceuticals, Pfizer Inc., Menlo Therapeutics, and Incyte Corporation. He is a consultant for Galderma S.A., Castle Biosciences, and Kinkisa Pharmaceuticals. He has received grant funding from Pfizer Inc., Kiniksa Pharmaceuticals, and Galderma S.A. S. Gabriel and R. Chavda are employed by Galderma S.A. Galderma is conducting clinical trials of nemolizumab for the treatment of pruritus in prurigo nodularis. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2020",

month = oct,

doi = "10.1016/j.jaip.2020.05.051",

language = "English (US)",

volume = "8",

pages = "3240--3241",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "9",

}

TY - JOUR

T1 - Prevalence of prurigo nodularis in the United States

AU - Whang, Katherine A.

AU - Mahadevan, Varun

AU - Bakhshi, Pegah R.

AU - Williams, Kyle A.

AU - Gabriel, Sylvie

AU - Chavda, Rajeev

AU - Kwatra, Shawn G.

N1 - Funding Information: Conflicts of interest: S. G. Kwatra is a scientific advisory board member for Regeneron Pharmaceuticals, Pfizer Inc., Menlo Therapeutics, and Incyte Corporation. He is a consultant for Galderma S.A., Castle Biosciences, and Kinkisa Pharmaceuticals. He has received grant funding from Pfizer Inc. , Kiniksa Pharmaceuticals , and Galderma S.A. S. Gabriel and R. Chavda are employed by Galderma S.A. Galderma is conducting clinical trials of nemolizumab for the treatment of pruritus in prurigo nodularis. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: S.G.K. received a research grant from the Skin of Color Society and is a recipient of a Medical Dermatology Career Development Award from the Dermatology Foundation . Funding Information: S.G.K. received a research grant from the Skin of Color Society and is a recipient of a Medical Dermatology Career Development Award from the Dermatology Foundation.Conflicts of interest: S. G. Kwatra is a scientific advisory board member for Regeneron Pharmaceuticals, Pfizer Inc., Menlo Therapeutics, and Incyte Corporation. He is a consultant for Galderma S.A., Castle Biosciences, and Kinkisa Pharmaceuticals. He has received grant funding from Pfizer Inc., Kiniksa Pharmaceuticals, and Galderma S.A. S. Gabriel and R. Chavda are employed by Galderma S.A. Galderma is conducting clinical trials of nemolizumab for the treatment of pruritus in prurigo nodularis. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85087303902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087303902&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2020.05.051

DO - 10.1016/j.jaip.2020.05.051

M3 - Article

C2 - 32531481

AN - SCOPUS:85087303902

SN - 2213-2198

VL - 8

SP - 3240

EP - 3241

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 9

ER -

Prevalence of prurigo nodularis in the United States

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this